Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer
This retrospective analysis confirms that mRNA expression-based risk stratification provides superior predictive accuracy compared to conventional clinicopathologic risk tools. Implementation of this gene signature could potentially reduce over-investigation and improve surveillance cost-effectiveness after TURBT in patients with primary high-risk NMIBC. These findings may transform the clinical management paradigm by enabling more personalized follow-up protocols based on molecular risk assessment.
Authors
- Aruna Korlimarla
- Hitesh Goswami
- Lista Paul (ORCID: https://orcid.org/0000-0002-5169-3578)
- N Srivatsa
- Nishtha Tanwar (ORCID: https://orcid.org/0009-0004-2784-5967)
- Ambili Narikot
- Vidya Veldore (ORCID: https://orcid.org/0000-0001-5989-4836)
- Peddagangannagari Sreekanthreddy (ORCID: https://orcid.org/0000-0003-2284-7889)
- Hari PS (ORCID: https://orcid.org/0000-0003-3580-962X)
- B. S. Srinath (ORCID: https://orcid.org/0009-0005-5534-5465)
- Rekha V. Kumar
- P. Patel Rahul
- Durgadevi Veeraiyan
Institutions
- GeneCare Research Institute (Japan) (JP)
- Cancer Hospital and Research Institute (IN)
- National Institute of Cancer Prevention and Research (IN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1186/s12885-025-14273-y
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02